{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T13:52:47Z","timestamp":1760622767804},"reference-count":89,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2010,5,19]],"date-time":"2010-05-19T00:00:00Z","timestamp":1274227200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Mycoses"],"published-print":{"date-parts":[[2011,9]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Sepsis is a leading cause of death in the intensive care unit (ICU), with <jats:italic>Candida<\/jats:italic> spp. in the forefront among the important pathogens. As recent studies have shown, survival outcome is strongly influenced by adequate antifungal therapy at an early stage that is often delayed by the time lag associated with microbiological diagnosis. Risk factor\u2010based prediction models have a high negative predictive value, but positive prediction of candidaemia in the individual patient remains elusive. New antigen\u2010 or DNA\u2010based methods for early diagnosis still await clinical validation. Their routine use is hampered by methodological issues. Species distribution of invasive <jats:italic>Candida<\/jats:italic> isolates in the ICU appears to be influenced primarily by age, previous hospitalisation and colonising species. In the context of the importance of adequate first\u2010line treatment, recent guidelines favour the use of echinocandins in critically ill patients with symptoms evoking high suspicion of invasive candidiasis. This is supported by robust clinical trial data, a few interactions and low toxicity. Fluconazole is characterised by reduced activity against some important <jats:italic>Candida<\/jats:italic> species, elevated rates of persistent infection seen in comparative trials. Amphotericin B deoxycholate should be considered obsolete in ICU patients because of its high toxicity. Invasive aspergillosis (IA) is a rare devastating infection in the general ICU population, but some centres have reported elevated incidences and underdiagnosis as determined in autopsy\u2010controlled studies. Treatment with mould\u2010active agents such as voriconazole must be initiated early in patients with suspected IA.<\/jats:p>","DOI":"10.1111\/j.1439-0507.2010.01885.x","type":"journal-article","created":{"date-parts":[[2010,5,19]],"date-time":"2010-05-19T19:09:52Z","timestamp":1274296192000},"page":"420-433","source":"Crossref","is-referenced-by-count":16,"title":["Current aspects of invasive candidiasis and aspergillosis in adult intensive care patients"],"prefix":"10.1111","volume":"54","author":[{"given":"A.","family":"Gl\u00f6ckner","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Karthaus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2011,9,13]]},"reference":[{"key":"e_1_2_17_2_2","doi-asserted-by":"publisher","DOI":"10.1086\/421946"},{"key":"e_1_2_17_3_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-006-0517-7"},{"key":"e_1_2_17_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2006.01.002"},{"key":"e_1_2_17_5_2","doi-asserted-by":"publisher","DOI":"10.1086\/496922"},{"key":"e_1_2_17_6_2","doi-asserted-by":"publisher","DOI":"10.1086\/378745"},{"key":"e_1_2_17_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0924-8579(08)70006-2"},{"key":"e_1_2_17_8_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-008-1338-7"},{"key":"e_1_2_17_9_2","doi-asserted-by":"publisher","DOI":"10.1097\/00000658-199308000-00001"},{"key":"e_1_2_17_10_2","doi-asserted-by":"publisher","DOI":"10.1097\/00003246-199906000-00019"},{"key":"e_1_2_17_11_2","doi-asserted-by":"publisher","DOI":"10.1097\/CCM.0b013e31816fc4cd"},{"key":"e_1_2_17_12_2","doi-asserted-by":"publisher","DOI":"10.1097\/00003246-199812000-00031"},{"key":"e_1_2_17_13_2","doi-asserted-by":"publisher","DOI":"10.1080\/13693780802369332"},{"key":"e_1_2_17_14_2","doi-asserted-by":"publisher","DOI":"10.1086\/321811"},{"key":"e_1_2_17_15_2","doi-asserted-by":"publisher","DOI":"10.1089\/109629600750067200"},{"key":"e_1_2_17_16_2","doi-asserted-by":"publisher","DOI":"10.1097\/CCM.0b013e3181a0f95d"},{"key":"e_1_2_17_17_2","doi-asserted-by":"publisher","DOI":"10.1097\/CCM.0b013e31819daa14"},{"key":"e_1_2_17_18_2","doi-asserted-by":"publisher","DOI":"10.1097\/00000658-199412000-00008"},{"key":"e_1_2_17_19_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.CCM.0000202208.37364.7D"},{"key":"e_1_2_17_20_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-007-0270-z"},{"key":"e_1_2_17_21_2","article-title":"Improvement of a clinical prediction rule for clinical trials on prophylaxis for invasive candidiasis in the intensive care unit","author":"Ostrosky\u2010Zeichner L","year":"2009","journal-title":"Mycoses"},{"key":"e_1_2_17_22_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.43.11.5425-5427.2005"},{"key":"e_1_2_17_23_2","article-title":"Recent epidemiology trends of Candida infections in cancer and non\u2010cancer patients","author":"Karthaus M","year":"2008","journal-title":"ICAAC"},{"key":"e_1_2_17_24_2","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1H516"},{"key":"e_1_2_17_25_2","doi-asserted-by":"publisher","DOI":"10.1097\/SLA.0b013e31819ed914"},{"key":"e_1_2_17_26_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.24507"},{"key":"e_1_2_17_27_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00029-06"},{"key":"e_1_2_17_28_2","article-title":"Mycological findings upon admission to a non\u2010surgical ICU \u2013 a prospective study","author":"Gloeckner A","year":"2005","journal-title":"ICC"},{"key":"e_1_2_17_29_2","doi-asserted-by":"publisher","DOI":"10.1213\/ane.0b013e3181607262"},{"key":"e_1_2_17_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2009.04.002"},{"key":"e_1_2_17_31_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00945-09"},{"key":"e_1_2_17_32_2","doi-asserted-by":"publisher","DOI":"10.1099\/jmm.0.47406-0"},{"key":"e_1_2_17_33_2","doi-asserted-by":"publisher","DOI":"10.1086\/432470"},{"key":"e_1_2_17_34_2","doi-asserted-by":"publisher","DOI":"10.1086\/528690"},{"key":"e_1_2_17_35_2","doi-asserted-by":"publisher","DOI":"10.1086\/528692"},{"key":"e_1_2_17_36_2","article-title":"The high mortality of Candida septic shock is explained by excessive delays in initiation of antifungal therapy","author":"Kumar A","year":"2007","journal-title":"ICAAC"},{"key":"e_1_2_17_37_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.09-0087"},{"key":"e_1_2_17_38_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.9.3640-3645.2005"},{"key":"e_1_2_17_39_2","doi-asserted-by":"publisher","DOI":"10.1086\/504810"},{"key":"e_1_2_17_40_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00601-06"},{"key":"e_1_2_17_41_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.CCM.0000298158.12101.41"},{"key":"e_1_2_17_42_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-149-2-200807150-00004"},{"key":"e_1_2_17_43_2","doi-asserted-by":"publisher","DOI":"10.1086\/596757"},{"key":"e_1_2_17_44_2","unstructured":"HerbrechtR Fl\u00fcckigerU GachotB RibaudP ThiebautA CordonnierC.Antifungal therapy in leukemia patients: 2009 update of the ECIL 1 and ECIL 2 guidelines.2009. URLhttp:\/\/www.ebmt.org\/5WorkingParties\/IDWP\/IDdocs_unproteced\/ECIL%203%20Antifungal%20therapy%20Update%202009.pdf. [accessed on 29 March 2010]."},{"key":"e_1_2_17_45_2","doi-asserted-by":"publisher","DOI":"10.1086\/505969"},{"key":"e_1_2_17_46_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-008-0622-5"},{"key":"e_1_2_17_47_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa066906"},{"key":"e_1_2_17_48_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1439-0507.2008.01645.x"},{"key":"e_1_2_17_49_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa021585"},{"key":"e_1_2_17_50_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)60605-9"},{"key":"e_1_2_17_51_2","doi-asserted-by":"publisher","DOI":"10.1086\/520980"},{"key":"e_1_2_17_52_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01726360"},{"key":"e_1_2_17_53_2","doi-asserted-by":"publisher","DOI":"10.1086\/374850"},{"key":"e_1_2_17_54_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00409-07"},{"key":"e_1_2_17_55_2","volume-title":"Fachinformation (Summary of Product Characteristics), Ecalta (Anidulafungin)","author":"Pfizer","year":"2009"},{"key":"e_1_2_17_56_2","volume-title":"Fachinformation (Summary of Product Characteristics), Cancidas (Caspofungin)","author":"MSD","year":"2008"},{"key":"e_1_2_17_57_2","volume-title":"Fachinformation (Summary of Product Characteristics), Mycamine (Micafungin)","author":"Astellas","year":"2008"},{"key":"e_1_2_17_58_2","doi-asserted-by":"publisher","DOI":"10.1248\/bpb.32.750"},{"key":"e_1_2_17_59_2","doi-asserted-by":"publisher","DOI":"10.1592\/phco.27.3.369"},{"key":"e_1_2_17_60_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkm125"},{"key":"e_1_2_17_61_2","unstructured":"EMEA.Mycamine Public Assessment Report. H\u2010734\u2010en6.2009. URLhttp:\/\/www.emea.europa.eu\/humandocs\/Humans\/EPAR\/mycamine\/mycamine[accessed on 29 March 2010]."},{"key":"e_1_2_17_62_2","unstructured":"FDA.Prescribing Information for Mycamine.2005. URLhttp:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2008\/021506s008lbl.pdf[accessed on 29 March 2010]."},{"key":"e_1_2_17_63_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2009.06.016"},{"key":"e_1_2_17_64_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199411173312001"},{"key":"e_1_2_17_65_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)67490-9"},{"key":"e_1_2_17_66_2","doi-asserted-by":"publisher","DOI":"10.1186\/cc6997"},{"key":"e_1_2_17_67_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-007-0305-5"},{"key":"e_1_2_17_68_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23466"},{"key":"e_1_2_17_69_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-6-21"},{"key":"e_1_2_17_70_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.CCM.0000201897.78123.44"},{"key":"e_1_2_17_71_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01568-07"},{"key":"e_1_2_17_72_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2007.10.014"},{"key":"e_1_2_17_73_2","article-title":"Conversion of intravenous echinocandins to oral azoles for invasive candidiasis: impact on outcomes and resource utilisation","author":"Davis S","year":"2008","journal-title":"ECCMID"},{"key":"e_1_2_17_74_2","doi-asserted-by":"publisher","DOI":"10.1086\/599376"},{"key":"e_1_2_17_75_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00211-08"},{"key":"e_1_2_17_76_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.6.1773-1780.2002"},{"key":"e_1_2_17_77_2","doi-asserted-by":"publisher","DOI":"10.1097\/MJT.0b013e3181a1afb7"},{"key":"e_1_2_17_78_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.CCM.0000208357.05675.C3"},{"key":"e_1_2_17_79_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dki491"},{"key":"e_1_2_17_80_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.CCM.0000178352.14703.49"},{"key":"e_1_2_17_81_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-009-1405-8"},{"key":"e_1_2_17_82_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-002-1540-y"},{"key":"e_1_2_17_83_2","doi-asserted-by":"publisher","DOI":"10.1097\/00000658-200104000-00010"},{"key":"e_1_2_17_84_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200401-093OC"},{"key":"e_1_2_17_85_2","doi-asserted-by":"publisher","DOI":"10.1086\/518852"},{"key":"e_1_2_17_86_2","doi-asserted-by":"publisher","DOI":"10.1086\/509917"},{"key":"e_1_2_17_87_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1439-0507.2007.01375.x"},{"key":"e_1_2_17_88_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200704-606OC"},{"key":"e_1_2_17_89_2","doi-asserted-by":"publisher","DOI":"10.1086\/525258"},{"key":"e_1_2_17_90_2","doi-asserted-by":"publisher","DOI":"10.1034\/j.1399-3062.2002.t01-2-02002.x"}],"container-title":["Mycoses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1439-0507.2010.01885.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1439-0507.2010.01885.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,14]],"date-time":"2023-10-14T04:07:26Z","timestamp":1697256446000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1439-0507.2010.01885.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,9]]},"references-count":89,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2011,9]]}},"alternative-id":["10.1111\/j.1439-0507.2010.01885.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1439-0507.2010.01885.x","archive":["Portico"],"relation":{},"ISSN":["0933-7407","1439-0507"],"issn-type":[{"value":"0933-7407","type":"print"},{"value":"1439-0507","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,9]]}}}